Skip to NavigationSkip to content

News

Top 10 news roundup
A number of new COVID-19 developments have emerged in April already: AstraZeneca has halted the trial of its COVID-19 vaccine on children amid blood-...
Cancer cell
Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first time ever.
Moderna have published antibody persistence data out to six months following the second dose of its COVID-19 vaccine (mRNA-1273) in The New England...
Results from Eli Lily and Incyte’s Phase III study, COV-BARRIER, evaluating baricitinib in the treatment of hospitalised COVID-19 patients did not...
Abbott have received CE Mark approval for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind tricuspid...
Novartis building
The MHRA and European Commission have both granted marketing authorisation to Novartis for its Kesimpta therapy, for the treatment of adult patients...
Gilead sign
The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).
The MHRA have recommended that people under the age of 30 not be offered the AstraZeneca COVID-19 vaccine, due to evidence linking the jab to rare...
Global Blood Therapeutics (GBT) have published the successful results from their Phase III study of Oxbryta (voxelotor) tablets in patients with...
Akili Interactive has announced a collaboration with Weill Cornell Medicine, New York-Presbyterian Hospital and Vanderbilt University Medical Center...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches